PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
visiongain

Press Release


Receive press releases from visiongain: By Email RSS Feeds:

"Report Predicts Asthma and COPD Drug Revenues Will Reach $43.8bn in 2015" Says Visiongain


A new report by Visiongain predicts that world asthma and COPD drug revenues will reach $43.8bn in 2015. That market generated $32.1bn in 2010, according to Asthma and COPD Therapies: World Market 2011-2021, published in August 2011.

London, United Kingdom, August 11, 2011 --(PR.com)-- Asthma and chronic obstructive pulmonary disease (COPD) are inflammatory disorders characterised by variable airflow obstruction and airway hyper-responsiveness to a variety of intrinsic, genetic and environmental stimuli. Those disorders are one of the leading causes of disability and death. Their prevalence and incidence are increasing worldwide.

At present, drug therapies aim for management of those disorders by use of inhaled corticosteroids (ICs), short and long-acting beta-agonists (SABAs/LABAs) and combination drugs. The asthma and COPD drug market is large, with six of the top ten drugs being blockbusters. The top three products had combined sales of $17.45 bn in 2010. Those drugs are GSK's Seretide/Advair, Merck's Singulair and Boehringer Ingelheim's Spiriva.

Several of the blockbuster treatments will lose patent protection this decade. Dr Syed Ahmed, senior healthcare industry analyst, said: "We estimate that $15 to $20bn worth of drugs in this segment will lose patent protection in the next five to seven years. Patients will benefit from cheaper generic products, while pharmaceutical companies have an opportunity to launch efficacious products to cater for several unmet needs in this market."

Visiongain forecasts that the overall asthma and COPD therapies market will grow steadily to 2021. Patients, healthcare providers and drug developers will benefit from new treatments, answering the therapeutic challenges, the report concludes. This new study adds to Visiongain's wide range of analytical reports in healthcare and other industry areas.

For sample pages of this report please visit

http://xrl.us/Asthma

Please contact Sara Peerun for an exec summary:
Email: Sara.peerun@visiongainglobal.com
Tel: +44 0207 3366100
Web: www.visiongain.com

Table of Contents

1. Executive Summary

2. Introduction to Asthma & COPD Therapies

3. The Asthma & COPD Therapies Market, 2011-2021

4. GlaxoSmithKline's Contribution to the Asthma & COPD Market

5. Merck's Contribution to the Asthma & COPD Market

6. Boehringer Ingelheim's Contribution to the Asthma & COPD Market

7. AstraZeneca's Contribution to the Asthma & COPD Market

8. Novartis' Contribution to the Asthma & COPD Market

9. SWOT Analysis: Factors Influencing the Market

10. Conclusions from Our Study

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About Visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

###
Contact Information
Visiongain
Sara Peerun
+44 020 7336 6100
Contact
www.visiongain.com

Click here to view the list of recent Press Releases from visiongain
Promote Your Business